GSK lifts emerging market bet with full control of Indonesia arm

April 11, 2014 Leave a comment

GSK lifts emerging market bet with full control of Indonesia arm

9:48am EDT

LONDON (Reuters) – GlaxoSmithKline is betting more on Indonesia by taking full control of its consumer healthcare unit in the country, underscoring a drive by the drugmaker to build up its presence in fast-growing emerging markets.

The move, announced on Friday, mirrors the British company’s strategy in India, where it recently increased its stake in local units.

GSK has paid 465 billion rupiahs ($40 million) to Sarasvati Venture Capital for the 30 percent of the Indonesian consumer healthcare operation it did not previously own, giving it 100 percent of a business that sells non-prescription products like Panadol painkillers and Sensodyne toothpaste.

At the same time, GSK has sold its non-core local Insto eye drops brand to Pharma Healthcare and agreed to divest its factory at Bogor, Indonesia, to PT Pharma Healthcare for a combined total of 133 billion rupiahs.

“This transaction is a further example of GSK focusing its business in strategically important growth markets such as Indonesia. It will also simplify operations in the Indonesian business,” David Redfern, GSK’s chief strategy officer, said.

GSK’s Indonesian consumer healthcare business has seen significant growth over the last five years, with net sales reaching close to 50 million pounds ($83 million) in 2013, up from around 16 million in 2008.

The company is committed to emerging markets as a key growth platform – based on rising demand for healthcare among growing middle class populations – despite recent problems in China, where sales have been hit by bribery allegations.

 

Filed under Health, Macro Trends

Unknown's avatarAbout bambooinnovator
Kee Koon Boon (“KB”) is the co-founder and director of HERO Investment Management which provides specialized fund management and investment advisory services to the ARCHEA Asia HERO Innovators Fund (www.heroinnovator.com), the only Asian SMID-cap tech-focused fund in the industry. KB is an internationally featured investor rooted in the principles of value investing for over a decade as a fund manager and analyst in the Asian capital markets who started his career at a boutique hedge fund in Singapore where he was with the firm since 2002 and was also part of the core investment committee in significantly outperforming the index in the 10-year-plus-old flagship Asian fund. He was also the portfolio manager for Asia-Pacific equities at Korea’s largest mutual fund company. Prior to setting up the H.E.R.O. Innovators Fund, KB was the Chief Investment Officer & CEO of a Singapore Registered Fund Management Company (RFMC) where he is responsible for listed Asian equity investments. KB had taught accounting at the Singapore Management University (SMU) as a faculty member and also pioneered the 15-week course on Accounting Fraud in Asia as an official module at SMU. KB remains grateful and honored to be invited by Singapore’s financial regulator Monetary Authority of Singapore (MAS) to present to their top management team about implementing a world’s first fact-based forward-looking fraud detection framework to bring about benefits for the capital markets in Singapore and for the public and investment community. KB also served the community in sharing his insights in writing articles about value investing and corporate governance in the media that include Business Times, Straits Times, Jakarta Post, Manual of Ideas, Investopedia, TedXWallStreet. He had also presented in top investment, banking and finance conferences in America, Italy, Sydney, Cape Town, HK, China. He has trained CEOs, entrepreneurs, CFOs, management executives in business strategy & business model innovation in Singapore, HK and China.

Leave a comment